Patterns of CRS with Teclistamab in Relapsed/Refractory Multiple Myeloma patients with Prior T-Cell Redirection Therapy
Key Points. Multiple myeloma patients previously treated with T-cell redirection therapy have significantly low risk of developing CRS with teclistamabPati